Clinical Trial Update: Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial of siltuximab for Large Granular Lymphocytic Leukemia has been terminated. The sponsor is H. Lee Moffitt Cancer Center and Research Insti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large Granular Lymphocytic Leukemia

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Large Granular Lymphocyte Leukemia | EARLY_Phase 1 | Status: TERMINATED